Mitochondrial Targeted Cancer Therapy
After a decade of research and dozens of publications, we have the first in class inhibitor of TRAP1, a HSP90 Chaperone, in mitochondria.
Gamitrinib
GA Mitochondrial Matrix Inhibitor
There have been many attempts at small molecule HSP90 inhibitors for cancer therapy.
None of the HSP90 inhibitors so far have the ability to accumulate in mitochondria.
Ours does.
Publications →
Background
Cancers typically have very high metabolic and energy demands to support their growth and ability to invade normal tissues and metastasize. The cancer cell is further challenged by a high mutational load often involving key cellular proteins, an environment starved of oxygen, as well as a significant imbalance of available nutrients to metabolic demands. The combination of high metabolic needs in a nutritional and oxygen starved environment places unique demands on cancer cells. Meeting these demands rests on the mitochondrial organelle, a specialized compartment of the cancer cell.
Gladius Therapeutics is a clinical stage biopharmaceutical company with a sole focus on developing therapeutics that disrupt mitochondrial function in the cancer cell.
Founding Team
Michael Seiden, M.D. Ph.D.
Co-Founder and CEO
Dr. Seiden is a senior oncologist and business executive with extensive experience in drug development and healthcare management.
He has served as the CEO of the Fox Chase Cancer Center (2007-2013) as well as the Chief Medical Officer and President of US Oncology (2013-2021) a McKesson Company.
In his last position, Dr. Seiden had oversight of US Oncology Research and 450 cancer delivery sites caring for over 1 million cancer patients across 23 states.
Dario Altieri M.D.
Co-Founder & Inventor
Dr. Altieri is an international expert in cancer biology with a 30-year history of funded research in the basic mechanisms of cancer growth and survival.
His previous roles included serving as a Professor at Yale in Pathology and the Founding Chair and Chair of Cancer Biology at the University of Massachusetts. Since 2010, he has served as the Cancer Center Director of the Ellen and Ronald Caplan NCI-designated cancer Center at Wistar. In 2015 he also assumed the role of President and Chief Executive Officer of The Wistar Institute.
Founded by practicioners and executives who have been friends for over a decade.
Licensed Patent Portfolio
1. Mitochondria-Targeted Anti-Tumour Agents (Docket Ref: UMMS07-64)
Assignee UMass Medical (Wistar controls commercialization pursuant to an IIA (Docket Ref: UMMS07-64))
Inventors: Dario C. Altieri, Byoung Heon Kang
60/993,195, filed September 10, 2007, PCT/US2008/075895, filed September 10, 2008
Canada CA2699794, issued July 19, 2016,China ZL200880115423.0, issued July 18, 2012
U.S. 12/208,207, issued 8,466,140, June 18, 2013 (Gamitrinib compositions), w/1087 days PTA
U.S.CON 15/070,657, issued 9,987,294, June 5, 2018 (methods of use)
2. Combination Therapies Targeting Mitochondria for Cancer Therapy
Assignee Wistar, Inventors: Dario C. Altieri, Jagadish C. Ghosh
U.S. 16/987,974, filed August 7, 2020 – earliest priority from 61/987,720 filed May 2, 2014 (methods of use)
3. Combination Therapies Targeting Mitochondrial Biogenesis for Cancer Therapy
Assignee Wistar, Inventors: Dario C. Altieri, Meenhard Herlyn, Gao Zhang, Qin Liu
U.S. 17/834,667, filed June 7, 2022 – earliest priority from 62/201,788, filed August 6, 2015 (methods of use)
4. Compositions and Methods for Treatment of MIC60 Depleted Cancers and Metastasis
Assignee Wistar, Inventors: Dario C. Altieri
63/270,883, filed October 22, 2021 and 63/371,600, filed August 16, 2022
PCT/US2022/078567, filed October 22, 2022 (biomarker compositions & methods of use)
5. Compositions and methods for Treating, Ameliorating and/or Preventing Cancer and Kits for the Same
Assignee Wistar , Inventors: Dario C. Altieri
63/315,871, filed March 2, 2021 (pharmaceutical compositions, methods of administration and treatment)
Sign up to receive news about
Gladius Therapeutics.